Cyclerion Therapeutics, Inc. (CYCN)
USD 2.85
(-13.26%)
USD 2.85
(-13.26%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | 297 Thousand | 3.32 Million | 2.29 Million | 4.5 Million | - |
| Cost of Revenue | - | 65 Thousand | 472 Thousand | - | - | 1.52 Million |
| Gross Profit | - | 232 Thousand | 2.84 Million | 2.29 Million | 4.5 Million | -1.52 Million |
| Operating Expenses | 9.64 Million | 44.66 Million | 57.63 Million | 85.23 Million | 129.54 Million | 115.25 Million |
| Selling, General and Administrative Expenses | 8.13 Million | 14.5 Million | 20.62 Million | 28.81 Million | 34.4 Million | 27.53 Million |
| Research and Development Expenses | 1.51 Million | 31.49 Million | 37.63 Million | 56.41 Million | 95.14 Million | 87.71 Million |
| Other Expenses | - | -1.32 Million | -622 Thousand | - | - | - |
| Cost and Expenses | 9.64 Million | 44.66 Million | 57.63 Million | 85.23 Million | 129.54 Million | 115.25 Million |
| Operating Income | -9.64 Million | -44.37 Million | -55.19 Million | -81.26 Million | -125.03 Million | -115.25 Million |
| Interest Expense | - | 294 Thousand | 16 Thousand | - | - | - |
| Income Tax Expense | - | -294 Thousand | 16 Thousand | -5.13 Million | -2.02 Million | 1.36 Million |
| Earnings before Tax | -12.59 Million | -44.07 Million | -51.64 Million | -77.8 Million | -123 Million | -115.25 Million |
| Net Income | -21.01 Million | -43.78 Million | -51.66 Million | -72.67 Million | -120.97 Million | -115.25 Million |
| Earnings Per Share Basic | -8.99 | -20.15 | -26.40 | -47.80 | -88.37 | -84.42 |
| Earnings Per Share Diluted | -8.99 | -20.15 | -26.40 | -47.80 | -88.37 | -84.42 |
| Weighted Average Shares Outstanding | 2.33 Million | 2.17 Million | 1.95 Million | 1.52 Million | 1.36 Million | 1.36 Million |
| Weighted Average Shares Outstanding (Diluted) | 2.33 Million | 2.17 Million | 1.95 Million | 1.52 Million | 1.36 Million | 1.36 Million |
| Gross Margin | - | 0.78 | 0.86 | 1.00 | 1.00 | - |
| EBIT Margin | - | -149.18 | -16.22 | -37.10 | -27.14 | - |
| Profit Margin | - | -147.42 | -15.56 | -31.65 | -26.84 | - |
| EBITDA | -12.59 Million | -18.18 Million | -55.19 Million | -81.26 Million | -122.33 Million | -113.72 Million |
| Earnings Before Tax Margin | - | -149.40 | -16.62 | -35.39 | -27.74 | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 1.38 Million | 1.61 Million | 9.64 Million | 1.79 Million | 2.71 Million | 4.24 Million |
| Selling, General and Administrative Expenses | 1.27 Million | 1.57 Million | - | 1.77 Million | 2.13 Million | 3.35 Million |
| Research and Development Expenses | 105 Thousand | 44 Thousand | - | 24 Thousand | 580 Thousand | 886 Thousand |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 1.38 Million | 1.61 Million | 9.64 Million | 1.79 Million | 2.71 Million | 4.24 Million |
| Operating Income | -1.38 Million | -1.61 Million | -9.64 Million | -1.79 Million | -6.01 Million | -4.24 Million |
| Interest Expense | - | - | - | -88 Thousand | - | - |
| Income Tax Expense | - | -43.27 Thousand | 8.42 Million | 17.06 Million | -16.88 Million | -122.08 Thousand |
| Earnings before Tax | -1.32 Million | -1.54 Million | -12.59 Million | -1.69 Million | -5.9 Million | -4.18 Million |
| Net Income | -1.32 Million | -1.54 Million | -21.01 Million | -1.69 Million | 7.56 Million | -4.18 Million |
| Earnings Per Share Basic | -0.53 | -0.62 | - | -0.68 | -3.36 | -1.83 |
| Earnings Per Share Diluted | -0.53 | -0.62 | - | -0.68 | -3.36 | -1.83 |
| Weighted Average Shares Outstanding | 2.51 Million | 2.49 Million | 2.33 Million | 2.47 Million | 2.43 Million | 2.28 Million |
| Weighted Average Shares Outstanding (Diluted) | 2.51 Million | 2.49 Million | 2.33 Million | 2.47 Million | 2.43 Million | 2.28 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -1.38 Million | -1.61 Million | - | -1.79 Million | 593 Thousand | -4.24 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
4166
LVTX
NVTQF
010820
STX
BUX